Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in...
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
November 08, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting
November 04, 2021 06:00 ET
|
Talaris Therapeutics, Inc.
First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with...
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction
October 29, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of...
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
October 28, 2021 16:36 ET
|
Talaris Therapeutics, Inc.
Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipientsPoster with additional data from Phase 2 study follow-up to be presented at...
Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
September 02, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
June 14, 2021 16:01 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
June 03, 2021 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Closing of Initial Public Offering
May 11, 2021 16:01 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...